Shafique Virani M.D.
Net Worth

Last updated:

What is Shafique Virani M.D. net worth?

The estimated net worth of Dr. Shafique Virani M.D. is at least $6,326,014 as of 16 Oct 2023. He owns shares worth $703,159 as insider, has earned $3,721,935 from insider trading and has received compensation worth at least $1,900,920 in Recursion Pharmaceuticals, Inc..

What is the salary of Shafique Virani M.D.?

Dr. Shafique Virani M.D. salary is $475,230 per year as Chief Corporation Devel. Officer in Recursion Pharmaceuticals, Inc..

How old is Shafique Virani M.D.?

Dr. Shafique Virani M.D. is 54 years old, born in 1971.

What stocks does Shafique Virani M.D. currently own?

As insider, Dr. Shafique Virani M.D. owns shares in one company:

Company Title Shares Price per share Total value
Recursion Pharmaceuticals, Inc. (RXRX) Chief Corporation Devel. Officer 140,351 $5.01 $703,159

What does Recursion Pharmaceuticals, Inc. do?

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

RXRX logo
RXRX
Recursion Pharmaceuticals, Inc.
$5.01

Shafique Virani M.D. insider trading

Recursion Pharmaceuticals, Inc.

Dr. Shafique Virani M.D. has made 22 insider trades between 2021-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 45,045 units of RXRX stock on 2 Jun 2021. As of 16 Oct 2023 he still owns at least 140,351 units of RXRX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Class A Common Stock 18,000 $2.22 $39,960
Sale
Class A Common Stock 18,000 $6.3 $113,400
Option
Stock Option (Right to Buy) 18,000 $2.22 $39,960
Sale
Class A Common Stock 18,000 $8.66 $155,880
Option
Class A Common Stock 18,000 $2.22 $39,960
Option
Stock Option (Right to Buy) 18,000 $2.22 $39,960
Option
Stock Option (Right to Buy) 18,000 $2.22 $39,960
Sale
Class A Common Stock 18,000 $9.25 $166,500
Option
Class A Common Stock 18,000 $2.22 $39,960
Option
Class A Common Stock 20,000 $2.22 $44,400
Sale
Class A Common Stock 20,000 $14.41 $288,200
Option
Stock Option (Right to Buy) 20,000 $2.22 $44,400
Sale
Class A Common Stock 20,000 $14.3 $286,000
Option
Stock Option (Right to Buy) 20,000 $2.22 $44,400
Sale
Class A Common Stock 30,000 $13.74 $412,200
Option
Class A Common Stock 30,000 $2.22 $66,600
Option
Stock Option (Right to Buy) 30,000 $2.22 $66,600
Sale
Class A Common Stock 30,000 $11.72 $351,600
Option
Stock Option (Right to Buy) 30,000 $2.22 $66,600
Option
Stock Option (Right to Buy) 30,000 $2.22 $66,600
Option
Class A Common Stock 30,000 $2.22 $66,600
Sale
Class A Common Stock 30,000 $9.41 $282,300
Option
Stock Option (Right to Buy) 30,000 $2.22 $66,600
Sale
Class A Common Stock 30,000 $9.67 $290,100
Sale
Class A Common Stock 17,865 $8.93 $159,534
Sale
Class A Common Stock 25,000 $8.58 $214,500
Sale
Class A Common Stock 1,768 $8.42 $14,887
Option
Stock Option (Right to Buy) 7,486 $2.22 $16,619
Option
Class A Common Stock 7,486 $2.22 $16,619
Sale
Class A Common Stock 7,486 $8.33 $62,358
Option
Stock Option (Right to Buy) 5,000 $2.22 $11,100
Option
Class A Common Stock 5,000 $2.22 $11,100
Sale
Class A Common Stock 10,000 $9.16 $91,560
Sale
Class A Common Stock 10,000 $8.85 $88,530
Option
Class A Common Stock 5,000 $2.22 $11,100
Option
Stock Option (Right to Buy) 5,000 $2.22 $11,100
Option
Class A Common Stock 5,000 $2.22 $11,100
Sale
Class A Common Stock 5,059 $12.7 $64,249
Sale
Class A Common Stock 4,941 $11.92 $58,872
Option
Stock Option (Right to Buy) 5,000 $2.22 $11,100
Option
Class A Common Stock 5,000 $2.22 $11,100
Option
Stock Option (Right to Buy) 5,000 $2.22 $11,100
Sale
Class A Common Stock 5,000 $11.21 $56,050
Sale
Class A Common Stock 5,000 $10.63 $53,130
Sale
Class A Common Stock 400 $13.97 $5,589
Sale
Class A Common Stock 9,600 $13.34 $128,045
Option
Stock Option (Right to Buy) 5,000 $2.22 $11,100
Option
Class A Common Stock 5,000 $2.22 $11,100
Option
Class A Common Stock 25,000 $2.22 $55,500
Sale
Class A Common Stock 30,000 $12.62 $378,450
Option
Stock Option (Right to Buy) 25,000 $2.22 $55,500
Option
Stock Option (Right to Buy) 45,045 $2.22 $100,000
Option
Class A Common Stock 45,045 $2.22 $100,000

Recursion Pharmaceuticals key executives

Recursion Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: